###### Key messages

-   We identified epigenetic susceptibility loci for cutaneous involvement in SLE using DNA methylation profiles in naïve CD4+ T cells.

-   Differentially methylated regions localized to genes mediating cell proliferation and apoptosis contribute to the epigenetic susceptibility to cutaneous involvement in SLE.

-   Cutaneous involvement in SLE is characterized by differential DNA methylation in genes involved in TAP-dependent processing and MHC-I antigen cross-presentation.

-   Novel targets that can help to better understand cutaneous manifestations in SLE have been identified.

Introduction {#s1}
============

Systemic lupus erythematosus (SLE) is a complex autoimmune disease characterised by autoantibody production and heterogeneous clinical manifestations. The aetiology of SLE remains incompletely understood, however there is increasing evidence for a role of DNA methylation changes in the pathogenesis of SLE.[@R1] DNA methylation is a lineage-specific epigenetic mechanism with an integral role in the immune system. This DNA modification, which typically refers to the methylation of the 5′ cytosine carbon of cytosine-guanine (CG) dinucleotides, is often a transcriptionally repressive mark able to alter gene accessibility and chromatin structure.[@R2] Through this effect, DNA methylation is capable of mediating cell differentiation and immune function.[@R3] Indeed, differentiation of naïve CD4+ T cells to T~H~1, T~H~2 and T~H~17 effector subsets is imparted by demethylation of IFNγ, IL-4/IL-5/IL-13 and IL-17A/IL-17F genes, respectively.[@R3] Importantly, aberrancies in DNA methylation can cause significant dysregulation of the immune system and have been associated with several autoimmune conditions including SLE.[@R1] [@R2] [@R4] We previously reported evidence linking type I interferon hyper-responsiveness in patients with SLE to transcriptional poising induced by DNA hypomethylation in naïve CD4+ T cells.[@R1]

In this study, we explore DNA methylation changes in naïve CD4+ T cells in patients with SLE with a history of malar rash or discoid rash to identify patterns of epigenetic susceptibility that are specific to patients with a history of these cutaneous manifestations. We identified differentially methylated (DM) sites unique to either cutaneous manifestation in SLE. In addition, we associate manifestation-specific differentially methylated regions (DMRs) to pathways related to environmental stress response, apoptosis and proliferation, and antigen processing and presentation.

Materials and methods {#s2}
=====================

Patient and control demographic information {#s2a}
-------------------------------------------

This study included three independent groups of patients with SLE and healthy matched controls. Each group consisted of eight patients with SLE with a history of malar rash, discoid rash or neither, and eight age (±5 years), sex and ethnicity matched healthy controls (see online supplementary table S1). All patients fulfilled the American College of Rheumatology classification criteria for SLE.[@R19] The American College of Rheumatology classification criteria for SLE met in each patient, and disease activity scores and criteria measured using the SLE Disease Activity Index and background medications at the time of enrolment in this study are shown in online supplementary tables S2 and S3. Patients and healthy controls included in this study signed an informed consent, and were recruited from the University of Michigan, Oklahoma Medical Research Foundation and the Henry Ford Health System.

Naïve CD4+ T cell DNA extraction {#s2b}
--------------------------------

From each study participant, 80 mL of whole blood was collected then subjected to Ficoll-gradient centrifugation (GE Healthcare Bio-Sciences AB, Uppsala, Sweden) to isolate peripheral blood mononuclear cells. Naïve CD4+ T cells were then isolated from peripheral blood mononuclear cells by negative selection magnetic bead cell separation (indirect labelling) using the Naïve CD4+ T Cell Isolation kit II (Miltenyi Biotec, Cambridge, Massachusetts, USA). The purity of the isolated naïve CD4+ T cells was confirmed \>95% using fluorochrome-conjugated antibodies targeting CD4 and CD45RA. DNA was then extracted using the DNeasy Blood and Tissue Kit (Qiagen, Valencia, California, USA) and bisulfite converted using the EZ DNA Methylation Kit (Zymo Research, Irvine, California, USA) for subsequent DNA methylation analysis.

DNA methylation studies {#s2c}
-----------------------

Genome-wide DNA methylation analysis was performed using the Infinium HumanMethylation450K BeadChip array (Illumina, San Diego, California, USA). DNA methylation levels were assessed at 485 577 methylation sites throughout the human genome, across 96% of UCSC cytosine-phosphate-guanine island (CpG islands) and 99% of RefSeq genes with an average of 17 sites per gene covering enhancers, promoter regions, 5′untranslated region (UTRs), 3′UTRs and gene bodies.

Statistical and bioinformatic analyses {#s2d}
--------------------------------------

Genome-wide DNA methylation analyses were performed using GenomeStudio methylation module V.1.9.0 (Illumina) as described previously.[@R1] Probe signal intensities were derived from raw image intensities then normalised using non-CG probes. Background subtraction was then performed based on unhybridised negative-control probe intensities. The normalised, background-subtracted signal intensities were used to calculate β values that represent DNA methylation levels on a scale of 0 to 1. Differential DNA methylation was calculated between patients with SLE and their respective matched controls within the malar rash, discoid rash or neither cutaneous involvement group using the GenomeStudio Illumina custom model described previously.[@R1] Probes with a single nucleotide polymorphism (SNP) within 10 bp of the 3′ probe end and probes with a detection p value ≥0.05 were excluded from the analysis. Differentially methylated sites were then filtered to include CG sites with a methylation difference (\|Δβ\|) ≥0.10 between patients and controls, and a differential methylation score (\|DiffScore\|) \> 22, which corresponds to a p value ≤0.01 after correction for multiple testing using a Benjamini and Hochberg false discovery rate of 5%. Hypomethylated regions (hypo-DMR) and hypermethylated regions (hyper-DMR) were identified as clusters of at least two respective hypomethylation or hypermethylation sites \<500 bp of each other using the clusterMaker function and Bump Hunter package for the R statistical programming language.[@R20] Regions were then filtered to exclude all hypo-DMR or hyper-DMR overlapping between different cutaneous manifestation groups to identify DMRs unique to each group. Network analyses were performed using GeneMANIA software with networks of gene-gene interactions based on attributes, coexpression, colocalisation, genetic interactions, pathways, physical interactions, predicted interactions and shared protein domains.[@R21] [@R22] Network analysis results are presented as false discovery rate corrected p values.

Results {#s3}
=======

Global DNA methylation patterns in cutaneous SLE {#s3a}
------------------------------------------------

Genome-wide DNA methylation profiles of peripheral blood naïve CD4+ T cells were created for SLE with a history of malar rash, discoid rash and neither cutaneous involvement by comparing DNA methylation levels at 485 577 sites between patients and matched healthy controls. We identified 615 DM sites in the malar group, 466 DM sites in the discoid group and 613 DM sites in the SLE group with neither cutaneous involvement. The majority of DM sites identified in each group were manifestation-specific, and present only in one group but not the remaining two groups ([figure 1](#LUPUS2015000101F1){ref-type="fig"}). Common to all groups, however, was a consistent hypomethylation in interferon-regulated genes (see online supplementary table S4). DNA methylation changes unique to malar rash, discoid rash or the SLE group with neither cutaneous involvement were subjected to further analysis to identify DNA methylation changes that predispose to specific cutaneous manifestations in SLE.

![Venn diagram depicting the distribution of differentially methylated (DM) CG sites (\|Δβ\|≥0.10) and associated genes between patients with systemic lupus erythematosus with a history of malar rash, discoid rash or neither cutaneous involvement, compared with healthy matched controls. Hypermethylated and hypomethylated CG sites are shown with ↑ and ↓ arrows, respectively.](lupus2015000101f01){#LUPUS2015000101F1}

The greatest methylation differences unique to malar rash were found in *GNAS* (Δβ=−0.27) encoding the G-protein α-stimulatory subunit and an intergenic locus at 7p22.2 (Δβ=0.33) ([table 1](#LUPUS2015000101TB1){ref-type="table"}, online supplementary table S4). In patients with discoid rash, the greatest unique methylation differences were found in *KNDC1* (Δβ=−0.21) which has a potential role in p53-mediated cell cycle arrest, an intergenic locus at 3q29 (Δβ=0.26), and *HLA-DRB6* (Δβ=0.26) ([table 1](#LUPUS2015000101TB1){ref-type="table"}, online supplementary table S4).[@R23] The greatest unique methylation differences in patients with SLE with no cutaneous involvement are found in *NFYA* (Δβ=−0.28) encoding a subunit of the NF-Y transcription factor and in *EXOC7* (Δβ=0.33) which encodes a component of the exocyst complex which is involved in exocytosis and membrane remodelling ([table 1](#LUPUS2015000101TB1){ref-type="table"}, online supplementary table S4).

###### 

Differential methylation analysis results showing the 10 most hypomethylated and hypermethylated CG sites (\|Δβ\|≥0.10) specific to (A) malar rash, (B) discoid rash or (C) neither cutaneous involvement in patients with systemic lupus erythematosus

  CG site ID                       Mean β case   Mean β control   Δβ      DiffScore   Location (HG19)    Gene name             Gene-relative location   CGI-relative location   Enhancer
  -------------------------------- ------------- ---------------- ------- ----------- ------------------ --------------------- ------------------------ ----------------------- ----------
  *(A) Malar rash*                                                                                                                                                              
  Hypomethylation                                                                                                                                                               
   cg09885502                      0.37          0.63             −0.27   −242.35     Chr20: 57463991    *GNAS*                TSS200, Body, 3′UTR      Island                  FALSE
   cg10090844                      0.27          0.51             −0.24   −200.61     Chr12: 132167226                                                  N_Shelf                 TRUE
   cg01821018                      0.60          0.84             −0.24   −272.08     Chr1: 59043280     *TACSTD2*             TSS200                   Island                  TRUE
   cg02891314                      0.49          0.71             −0.22   −171.35     Chr5: 179741120    *GFPT2*               Body                     Island                  FALSE
   cg23221052                      0.45          0.67             −0.22   −158.78     Chr5: 179740743    *GFPT2*               Body                     Island                  FALSE
   cg04863005                      0.53          0.74             −0.21   −158.15     Chr1: 59043208     *TACSTD2*             TSS200                   Island                  TRUE
   cg13944838                      0.52          0.73             −0.20   −144.11     Chr5: 179740914    *GFPT2*               Body                     Island                  FALSE
   cg26220594                      0.28          0.48             −0.20   −129.25     Chr1: 19110978                                                    S_Shore                 TRUE
   cg24853868                      0.39          0.59             −0.19   −112.67     Chr1: 146555624                                                   N_Shore                 FALSE
   cg01694488                      0.78          0.96             −0.18   −328.93     Chr4: 1580172                                                     Island                  FALSE
  Hypermethylation                                                                                                                                                              
   cg19214707                      0.65          0.32             0.33    341.10      Chr7: 3157722                                                                             TRUE
   cg15591384                      0.75          0.49             0.26    341.10      Chr6: 32525960     *HLA-DRB6*            Body                                             FALSE
   cg17178900                      0.54          0.28             0.26    341.10      Chr1: 205818956    *PM20D1*              Body                     Island                  TRUE
   cg22355889                      0.33          0.08             0.25    341.10      Chr11: 107461585   *LOC643923, ELMOD1*   TSS1500, TSS1500         N_Shore                 FALSE
   cg26354017                      0.50          0.26             0.24    341.10      Chr1: 205819088    *PM20D1*              1stExon                  Island                  TRUE
   cg14159672                      0.50          0.26             0.24    341.10      Chr1: 205819179    *PM20D1*              1stExon                  Island                  TRUE
   cg11224582                      0.39          0.15             0.24    341.10      Chr12: 4919138     *KCNA6*               5′UTR, 1stExon           Island                  FALSE
   cg19870512                      0.33          0.10             0.24    341.10      Chr12: 4919081     *KCNA6*               5′UTR, 1stExon           Island                  FALSE
   cg07167872                      0.48          0.24             0.24    341.10      Chr1: 205819463    *PM20D1*              TSS200                   S_Shore                 FALSE
   cg10671668                      0.32          0.09             0.23    341.10      Chr12: 4919230     *KCNA6*               1stExon                  Island                  FALSE
  *(B) Discoid rash*                                                                                                                                                            
  Hypomethylation                                                                                                                                                               
   cg24668570                      0.09          0.30             −0.21   −254.37     Chr10: 134973778   *KNDC1*               TSS200                   Island                  FALSE
   cg18480627                      0.42          0.63             −0.21   −137.10     Chr2: 130795582    *LOC440905*           Body                     Island                  FALSE
   cg24088508                      0.26          0.47             −0.21   −146.58     Chr1: 38156462     *C1orf109*            TSS1500                  N_Shore                 FALSE
   cg19214707                      0.31          0.52             −0.21   −133.32     Chr7: 3157722                                                                             TRUE
   cg26762873                      0.68          0.88             −0.20   −228.93     Chr11: 5879799     *OR52E8*              TSS1500                                          FALSE
   cg01797371                      0.18          0.36             −0.19   −139.72     Chr3: 195578240                                                                           FALSE
   cg20917491                      0.15          0.34             −0.19   −149.47     Chr3: 195578259                                                                           FALSE
   cg08103988                      0.49          0.67             −0.19   −109.96     Chr17: 6558365                                                    Island                  FALSE
   cg07157030                      0.45          0.63             −0.18   −95.79      Chr14: 63671356    *RHOJ*                5′UTR, 1stExon                                   TRUE
   cg05779406                      0.37          0.54             −0.18   −90.21      Chr7: 1198841      *ZFAND2A*             5′UTR                    N_Shore                 FALSE
  Hypermethylation                                                                                                                                                              
   cg01079515                      0.94          0.68             0.26    341.63      Chr3: 195576629                                                                           FALSE
   cg00103771                      0.67          0.41             0.26    341.63      Chr6: 32525805     *HLA-DRB6*            Body                                             FALSE
   cg23350716                      0.72          0.47             0.25    341.63      Chr1: 147956744    *PPIAL4B, PPIAL4A*    TSS1500, TSS1500                                 FALSE
   cg05357209                      0.42          0.17             0.25    341.63      Chr7: 872208       *UNC84A*              5′UTR, Body                                      TRUE
   cg06550200                      0.92          0.69             0.23    341.63      Chr5: 1325588      *CLPTM1L*             Body                                             FALSE
   cg08477687                      0.57          0.35             0.22    341.63      Chr1: 566570       *MIR1977*             TSS1500                                          FALSE
   cg01694488                      0.95          0.73             0.22    341.63      Chr4: 1580172                                                     Island                  FALSE
   cg02239258                      0.58          0.36             0.22    341.63      Chr8: 8241752                                                     N_Shore                 FALSE
   cg12303247                      0.88          0.67             0.21    341.63      Chr1: 155853542    *SYT11*               3′UTR                                            TRUE
   cg03213289                      0.52          0.32             0.19    114.27      Chr20: 61660250                                                   Island                  FALSE
  *(C) No cutaneous involvement*                                                                                                                                                
  Hypomethylation                                                                                                                                                               
   cg04346459                      0.71          0.99             −0.28   −338.22     Chr6: 41068666     *NFYA, LOC221442*     3′UTR, TSS200            Island                  TRUE
   cg25110423                      0.70          0.96             −0.26   −338.22     Chr6: 41068646     *NFYA, LOC221442*     3′UTR, TSS200            Island                  TRUE
   cg26893861                      0.26          0.49             −0.22   −167.87     Chr17: 41843967    *DUSP3*               3′UTR                                            FALSE
   cg19418458                      0.42          0.64             −0.22   −154.86     Chr7: 158789849                                                   Island                  FALSE
   cg10890302                      0.28          0.49             −0.21   −142.85     Chr6: 32064246     *TNXB*                Body                     Island                  FALSE
   cg14911689                      0.33          0.54             −0.21   −135.21     Chr12: 739980      *NINJ2*               Body                                             FALSE
   cg22531183                      0.03          0.24             −0.20   −302.51     Chr19: 50554451    *FLJ26850*            Body                     Island                  FALSE
   cg01079515                      0.73          0.93             −0.20   −312.22     Chr3: 195576629                                                                           FALSE
   cg01992382                      0.24          0.44             −0.20   −140.47     Chr6: 32064212     *TNXB*                Body                     Island                  FALSE
   cg05357209                      0.15          0.34             −0.20   −175.62     Chr7: 872208       *UNC84A*              5′UTR, Body                                      TRUE
  Hypermethylation                                                                                                                                                              
   cg26287080                      0.85          0.52             0.33    340.66      Chr17: 74086286    *EXOC7*               Body                                             FALSE
   cg08479752                      0.67          0.37             0.30    340.66      Chr19: 54567279    *VSTM1*               TSS200                                           FALSE
   cg16066505                      0.84          0.55             0.29    340.66      Chr2: 171316530    *MYO3B*               Body                                             FALSE
   cg25225073                      0.30          0.06             0.24    340.66      Chr14: 90528983    *KCNK13*              Body                     S_Shore                 FALSE
   cg18025438                      0.63          0.39             0.24    340.66      Chr1: 228756789                                                   Island                  FALSE
   cg16154810                      0.41          0.18             0.23    340.66      Chr22: 47135258    *CERK*                TSS1500                                          FALSE
   cg13830619                      0.93          0.71             0.22    340.66      Chr12: 9555480                                                                            FALSE
   cg17783317                      0.53          0.31             0.22    340.66      Chr19: 54567123    *VSTM1*               1stExon, 5′UTR                                   FALSE
   cg24247231                      0.52          0.31             0.21    340.66      Chr15: 67904302    *MAP2K5*              Body                                             TRUE
   cg07784793                      0.91          0.70             0.20    340.66      Chr5: 33794720     *ADAMTS12*            Body                                             TRUE

SLE manifestation-specific DMR analysis {#s3b}
---------------------------------------

Next, we identified genomic regions with extensive DNA methylation differences in patients with SLE with malar rash, discoid rash or no cutaneous involvement compared with their respective controls. For each SLE group studied, unique DMRs were defined as genomic ranges of at least two CG sites within a 500 bp window that are uniquely hypomethylated or hypermethylated in each patient group subset compared with healthy controls, but not in the two remaining SLE groups. Our data for malar rash SLE showed 14 hypomethylated regions (hypo-DMRs) and 22 hypermethylated regions (hyper-DMRs) ([table 2](#LUPUS2015000101TB2){ref-type="table"}). The most extensive region contains 13 hypermethylated sites (mean Δβ=0.15) in *LY6G5C,* a leucocyte antigen-6 gene of the major histocompatibility (MHC) class III genomic region. In patients with discoid rash, we show 17 hypo-DMRs and 20 hyper-DMRs with the most extensive DMR containing a cluster of 11 hypermethylated sites (mean Δβ=0.16) within *RNF39* (*HZF*)*,* a gene of the MHC class I genomic region encoding haematopoietic zinc finger protein ([table 2](#LUPUS2015000101TB2){ref-type="table"}).

###### 

Unique differentially methylated regions (DMRs) in naïve CD4+ T cells from patients with systemic lupus erythematosus with a history of (A) malar rash, (B) discoid rash or (C) neither cutaneous involvement

  DMR gene                         DMR location                  \# DM sites in DMR   Mean β case   Mean β control   Mean Δβ
  -------------------------------- ----------------------------- -------------------- ------------- ---------------- ---------
  *(A) Malar rash*                                                                                                   
  Hypo-DMR                                                                                                           
  * MIR886*                        Chr5: 135416331--135416412    6                    0.33          0.44             −0.12
  * TACSTD2*                       Chr1: 59043199--59043280      4                    0.51          0.70             −0.19
  * CTBP1, C4orf42*                Chr4: 1243980--1244024        4                    0.64          0.76             −0.12
  * GFPT2*                         Chr5: 179740743--179741120    3                    0.49          0.70             −0.21
  * C1orf86, LOC100128003*         Chr1: 2121039--2121349        2                    0.38          0.51             −0.13
   (Intergenic)                    Chr5: 1857306--1857477        2                    0.54          0.68             −0.14
  * HLAH, HLAG, HLAJ, HCG4B*       Chr6: 29895175--29895187      2                    0.25          0.35             −0.10
   (Intergenic)                    Chr6: 156983263--156983315    2                    0.76          0.86             −0.11
  * SVOPL*                         Chr7: 138349158--138349443    2                    0.44          0.55             −0.10
  * TRIM69*                        Chr15: 45028083--45028098     2                    0.56          0.66             −0.10
  * JPH3*                          Chr16: 87682036--87682142     2                    0.67          0.79             −0.12
  * LOC728392*                     Chr17: 5403337--5403516       2                    0.53          0.63             −0.10
  * RUNX1*                         Chr21: 36258423--36258497     2                    0.28          0.39             −0.11
  * RUNX1*                         Chr21: 36259067--36259383     2                    0.29          0.41             −0.11
  Hyper-DMR                                                                                                          
  * LY6G5C*                        Chr6: 31650735--31651151      13                   0.69          0.54             0.15
  * PM20D1*                        Chr1: 205818956--205819492    7                    0.46          0.24             0.22
  * HTR2A*                         Chr13: 47472138--47472349     5                    0.62          0.47             0.16
   (Intergenic)                    Chr3: 196705629--196705898    4                    0.51          0.38             0.13
  * KCNA6*                         Chr12: 4918848--4919230       4                    0.33          0.10             0.23
   (Intergenic)                    Chr5: 154026371--154026448    3                    0.45          0.33             0.12
  * MUC5B*                         Chr11: 1283875--1283970       3                    0.23          0.10             0.13
  * NINJ2*                         Chr12: 739980--740338         3                    0.51          0.32             0.19
  * CRIP2*                         Chr14: 105945022--105945685   3                    0.62          0.49             0.13
  * HOOK2*                         Chr19: 12876846--12877000     3                    0.48          0.33             0.15
  * THADA*                         Chr2: 43398171--43398339      2                    0.50          0.36             0.14
  * HDAC4*                         Chr2: 240142694--240142806    2                    0.67          0.54             0.13
   (Intergenic)                    Chr8: 43132451--43132507      2                    0.52          0.41             0.11
   (Intergenic)                    Chr11: 128694184--128694303   2                    0.55          0.44             0.11
  * PLEKHG6*                       Chr12: 6419570--6419575       2                    0.40          0.29             0.11
   (Intergenic)                    Chr12: 11700321--11700489     2                    0.90          0.78             0.13
  * SLC38A4*                       Chr12: 47219737--47219793     2                    0.46          0.34             0.12
   (Intergenic)                    Chr13: 23309892--23309930     2                    0.66          0.53             0.13
  * LIG4*                          Chr13: 108867111--108867154   2                    0.50          0.38             0.12
  * DEF8*                          Chr16: 90016020--90016061     2                    0.73          0.57             0.16
  * DHX58*                         Chr17: 40259724--40259828     2                    0.33          0.21             0.12
  * LASS4*                         Chr19: 8273505--8273693       2                    0.57          0.46             0.11
  *(B) Discoid rash*                                                                                                 
  Hypo-DMR                                                                                                           
   (Intergenic)                    Chr3: 195578040--195578280    5                    0.12          0.28             −0.16
  * TAP1*                          Chr6: 32819911--32820214      4                    0.34          0.45             −0.11
  * RFPL2*                         Chr22: 32599511--32599648     4                    0.40          0.52             −0.12
  * PRDM9*                         Chr5: 23507573--23507617      3                    0.69          0.80             −0.11
  * RPH3AL*                        Chr17: 154420--154671         3                    0.38          0.49             −0.11
  * C1orf109*                      Chr1: 38156462--38156652      2                    0.28          0.45             −0.17
  * SPINK9*                        Chr5: 147699718--147699892    2                    0.48          0.59             −0.11
  * LY6G5C*                        Chr6: 31651020--31651029      2                    0.62          0.74             −0.12
  * PSMB8*                         Chr6: 32810706--32810833      2                    0.50          0.63             −0.13
  * RHOJ*                          Chr14: 63671356--63671737     2                    0.43          0.60             −0.17
  * BAIAP3*                        Chr16: 1393584--1393797       2                    0.56          0.68             −0.12
   (Intergenic)                    Chr16: 53407722--53407808     2                    0.50          0.64             −0.13
   (Intergenic)                    Chr17:6558365--6558440        2                    0.50          0.67             −0.16
   (Intergenic)                    Chr17: 37024020--37024042     2                    0.29          0.42             −0.13
  * TBC1D16*                       Chr17: 77997833--77997997     2                    0.83          0.95             −0.11
  * SBNO2*                         Chr19: 1155030--1155184       2                    0.81          0.94             −0.13
  * C21orf81*                      Chr21: 15352608--15352983     2                    0.35          0.48             −0.13
  Hyper-DMR                                                                                                          
  * RNF39*                         Chr6: 30039142--30039524      11                   0.47          0.30             0.16
   (Intergenic)                    Chr7: 158789849--158790115    3                    0.55          0.42             0.14
   (Intergenic)                    Chr10: 43846281--43846539     3                    0.35          0.22             0.13
  * MIPEPP3*                       Chr13: 21900426--21900810     3                    0.60          0.48             0.12
  * ZNF714*                        Chr19: 21264896--21265421     3                    0.39          0.26             0.14
  * C1orf65*                       Chr1: 223566761--223567173    2                    0.39          0.29             0.10
  * MYT1L*                         Chr2: 1801628--1802045        2                    0.70          0.59             0.11
  * TMEM175*                       Chr4: 940644--940893          2                    0.63          0.52             0.11
   (Intergenic)                    Chr5: 74350132--74350214      2                    0.38          0.27             0.11
  * GFPT2*                         Chr5: 179740743--179740914    2                    0.60          0.47             0.13
  * TRIM31*                        Chr6: 30079265--30079280      2                    0.63          0.51             0.12
   (Intergenic)                    Chr6: 167559851--167559913    2                    0.59          0.45             0.14
  * RADIL*                         Chr7: 4848683--4848814        2                    0.24          0.10             0.13
   (Intergenic)                    Chr8: 58055876--58056113      2                    0.50          0.38             0.12
  * FGFR2*                         Chr10: 123355268--123355576   2                    0.47          0.37             0.10
  * RAD51B*                        Chr14: 69095570--69095679     2                    0.43          0.32             0.11
   (Intergenic)                    Chr15: 66947568--66947617     2                    0.37          0.26             0.12
  * SMAD3*                         Chr15: 67356838--67356942     2                    0.69          0.59             0.11
  * SPIB*                          Chr19: 50931432--50931515     2                    0.32          0.20             0.12
   (Intergenic)                    Chr20: 61659980--61660250     2                    0.58          0.41             0.17
  *(C) No cutaneous involvement*                                                                                     
  Hypo-DMR                                                                                                           
  * TNXB*                          Chr6: 32063607--32064582      15                   0.34          0.49             −0.15
  * NFYA, LOC221442*               Chr6: 41068646--41068752      5                    0.76          0.96             −0.21
  * MUC4*                          Chr3: 195489306--195489909    4                    0.63          0.77             −0.13
  * * (Intergenic)                 Chr7: 158789723--158790115    4                    0.43          0.59             −0.16
  * RAD51B*                        Chr14: 69095057--69095679     4                    0.31          0.44             −0.12
  * * (Intergenic)                 Chr1: 75590912--75591353      3                    0.34          0.46             −0.12
  * * (Intergenic)                 Chr6: 28447087--28447115      3                    0.30          0.42             −0.12
  * NINJ2*                         Chr12: 739980--740338         3                    0.38          0.57             −0.20
  * KCNA6*                         Chr12: 4919081--4919230       3                    0.25          0.38             −0.13
  * LMTK3*                         Chr19: 49000743--49000998     3                    0.65          0.76             −0.12
  * LMTK3*                         Chr19: 49001890--49002477     3                    0.59          0.71             −0.12
  * MYT1L*                         Chr2: 1817263--1817409        2                    0.58          0.70             −0.11
  * * (Intergenic)                 Chr4: 1550089--1550194        2                    0.66          0.77             −0.12
  * * (Intergenic)                 Chr4: 6010075--6010164        2                    0.46          0.56             −0.11
  * RGS14*                         Chr5: 176797920--176797999    2                    0.46          0.57             −0.12
  * RNF39*                         Chr6: 30039202--30039442      2                    0.32          0.45             −0.13
  * VARS2*                         Chr6: 30882641--30882708      2                    0.44          0.57             −0.13
  * TAP2*                          Chr6: 32805548--32805570      2                    0.55          0.67             −0.12
  * HOXA5*                         Chr7: 27183375--27183694      2                    0.68          0.79             −0.11
  * PTPRN2*                        Chr7: 158046166--158046222    2                    0.68          0.85             −0.17
  * * (Intergenic)                 Chr8: 1321333--1321375        2                    0.40          0.53             −0.12
  * * (Intergenic)                 Chr10: 130726624--130726701   2                    0.68          0.80             −0.12
  * TRIM5*                         Chr11: 5960015--5960081       2                    0.69          0.80             −0.11
  * STAT3*                         Chr17: 40489584--40489785     2                    0.27          0.40             −0.13
  * FLJ26850*                      Chr19: 50554451--50554510     2                    0.06          0.22             −0.16
  * NLRP2*                         Chr19: 55477653--55477810     2                    0.51          0.62             −0.11
  * HLCS*                          Chr21: 38362725--38362727     2                    0.57          0.71             −0.14
  * C21orf56*                      Chr21: 47604166--47604291     2                    0.24          0.38             −0.14
  Hyper-DMR                                                                                                          
  * NAPRT1*                        Chr8: 144659831--144660772    5                    0.37          0.23             0.14
  * GSTM5*                         Chr1: 110254662--110254709    3                    0.47          0.35             0.12
  * * (Intergenic)                 Chr10: 1939618--1939683       3                    0.67          0.51             0.16
  * CD101*                         Chr1: 117544206--117544416    2                    0.19          0.08             0.11
  * *(Intergenic)                  Chr2: 731298--731519          2                    0.80          0.67             0.13
   (Intergenic)                    Chr2: 173539262--173539542    2                    0.50          0.40             0.11
  * PRDM9*                         Chr5: 23507594--23507617      2                    0.74          0.64             0.11
  * FLOT1*                         Chr6: 30706647--30706654      2                    0.68          0.57             0.11
  * C11orf21, TSPAN32*             Chr11: 2322507--2322517       2                    0.21          0.10             0.12
   (Intergenic)                    Chr12: 19557334--19557343     2                    0.25          0.13             0.11
  * RARG*                          Chr12: 53612551--53612734     2                    0.53          0.41             0.12
  * VSTM1*                         Chr19: 54567123--54567279     2                    0.60          0.34             0.26
  * SPATC1L*                       Chr21: 47581042--47581405     2                    0.61          0.50             0.11
  * CERK*                          Chr22: 47135171--47135258     2                    0.32          0.13             0.19
  * BCOR*                          ChrX: 39956534--39956558      2                    0.31          0.19             0.12
  * BCOR*                          ChrX: 39958040--39958196      2                    0.34          0.20             0.14

Common to both cutaneous rashes are DMRs in an intergenic region in 7p22.3 and in *PRIC285* which encodes a transcriptional coactivator of peroxisome proliferator-activated receptor (PPAR)α and PPARγ (see online supplementary table S5).[@R24] [@R25] In patients with SLE with no cutaneous involvement, we identified 28 hypo-DMRs and 16 hyper-DMRs with the most extensive region containing 15 hypomethylated sites (mean Δβ=−0.15) within *TNXB*, a gene of the MHC class III genomic region encoding tenascin XB extracellular matrix glycoprotein ([table 2](#LUPUS2015000101TB2){ref-type="table"}). In all three patient subset groups, we identified a shared hypo-DMR in *IFI44L* (malar rash mean Δβ=−0.20, discoid rash mean Δβ=−0.16 and neither cutaneous involvement mean Δβ=−0.15) and *GSTT1* (malar rash mean Δβ=−0.14, discoid rash mean Δβ=−0.15 and neither cutaneous involvement mean Δβ=−0.15) (see online supplementary table S5). In addition, we identified a shared hyper-DMR in *GSTTP1* (malar rash mean Δβ=0.16, discoid rash mean Δβ=0.15 and neither cutaneous involvement mean Δβ=0.16).

Gene network analysis of manifestation-specific DMRs {#s3c}
----------------------------------------------------

We then performed gene network analyses to assess relationships between the manifestation-specific DMR genes. Results for malar rash and discoid rash hypo-DMR analyses showed enrichment in genes functioning in antigen peptide transporter (TAP)-dependent antigen processing and presentation of exogenous peptides via MHC class I (p=3.66×10^−18^ in malar and p=3.67×10^−13^ in discoid) ([figure 2](#LUPUS2015000101F2){ref-type="fig"}, [table 3](#LUPUS2015000101TB3){ref-type="table"}, online supplementary table S6). This pathway was not significantly enriched in genes with unique hypo-DMR in patients with neither cutaneous involvement (p\>0.05) ([figure 2](#LUPUS2015000101F2){ref-type="fig"}, online supplementary table S6). Network analyses were also performed for hyper-DMR genes, yet no functions were enriched in either discoid rash or neither cutaneous involvement groups. However, malar hyper-DMR genes were highly enriched in functions associated with type I interferon response (p=1.11×10^−21^) (see online supplementary figure S1, online supplementary table S7). It should be noted, however, that these hypermethylated interferon-related DMR genes are more specifically enriched in negative regulation of type I interferon production (p=4.83×10^−4^) and are different from the interferon-regulated genes that constitute the interferon signature known to be hypomethylated in SLE. Indeed, SLE interferon-signature genes were consistently hypomethylated in all three SLE groups in this study (see online supplementary table S4).

###### 

Network analysis results are shown for genes with unique hypomethylated regions (hypo-DMRs) in naïve CD4+ T cells from patients with systemic lupus erythematosus (SLE) with a history of malar rash, discoid rash or neither cutaneous involvement

  -------------------------------------------------------------------------------------------------- ----------
  Malar rash                                                                                         
   Antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent   3.66E-18
   Antigen processing and presentation of exogenous peptide antigen via MHC class I                  3.66E-18
   Antigen processing and presentation of peptide antigen via MHC class I                            2.65E-17
   Peptide antigen binding                                                                           1.87E-15
   Antigen processing and presentation of exogenous peptide antigen                                  1.91E-14
  Discoid rash                                                                                       
   Antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent   3.67E-13
   Antigen processing and presentation of exogenous peptide antigen via MHC class I                  3.67E-13
   Antigen processing and presentation of peptide antigen via MHC class I                            1.73E-12
   Peptide antigen binding                                                                           2.57E-12
   Antigen processing and presentation                                                               1.07E-10
  No cutaneous involvement                                                                           
   Protein trimerisation                                                                             1.60E-03
   Type I interferon signalling pathway                                                              5.85E-02
   Cellular response to type I interferon                                                            5.85E-02
   Response to type I interferon                                                                     5.85E-02
   Antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent   5.85E-02
  -------------------------------------------------------------------------------------------------- ----------

For each SLE manifestation group, results are shown for the five most significantly enriched functions. All network analyses were performed using GeneMANIA software.

DMR, differentially methylated regions; MHC, major histocompatibility.

![Network analysis results showing relationships among genes with hypomethylated regions (hypo-DMRs) specific to patients with systemic lupus erythematosus with a history of (A) malar rash, (B) discoid rash or (C) neither cutaneous involvement. Manifestation-specific hypo-DMR genes and network-associated genes are represented by blue and grey nodes, respectively. The lines connecting the nodes depict gene-gene relationships based on coexpression (purple), colocalisation (blue), genetic interactions (green), physical interactions (pink), and shared protein domains (yellow). Line thickness is relative to the strength of the gene-gene relationship. All network analyses were performed using GeneMANIA software. DMR, differentially methylated region.](lupus2015000101f02){#LUPUS2015000101F2}

Discussion {#s4}
==========

DNA methylation is a stable and heritable epigenetic modification that has a considerable effect on naïve CD4+ T cell differentiation and immune function. Aberrancies in DNA methylation are found in several autoimmune diseases including SLE.[@R15] [@R26] Furthermore, robust demethylation of interferon-regulated genes in naïve CD4+ T cells in SLE has been associated with a hyper-responsive type I interferon signature in patients with SLE.[@R1] Not surprisingly, demethylation of these same interferon-regulated genes was common to all SLE groups with malar, discoid or neither cutaneous manifestation (see online supplementary table S4). In this study, we further investigate the important link between naïve CD4+ T cells and SLE pathogenesis in a clinical manifestation-specific manner with an in-depth analysis of aberrant DNA methylation in naïve CD4+ T cells from patients with SLE with a history of malar rash or discoid rash. This is accomplished with a case-control study design involving independent genome-wide DNA methylation analyses for SLE with a history of malar rash, discoid rash or neither cutaneous involvement. In each analysis, patients with SLE in each of the manifestation groups were compared with healthy controls carefully matched for age, sex and ethnicity on a one-by-one basis. We then excluded DM sites that were common between the manifestation groups to characterise DNA methylation changes that are unique to only malar rash or discoid rash.

Our global DNA methylation profiles showed distinguishable manifestation-specific differences between each SLE group with 80.7% unique DM sites (229 hypomethylated and 267 hypermethylated CGs) for malar rash, and 76.4% unique DM sites (152 hypomethylated and 204 hypermethylated CGs) for discoid rash. In addition, we identified 14 hypo-DMRs and 22 hyper-DMRs unique to malar rash and 17 hypo-DMRs and 20 hyper-DMRs unique to discoid rash. Interestingly, several DMRs in either cutaneous manifestation are associated with genes mediating cell proliferation and apoptosis pathways. In patients with a history of malar rash, the most extensive malar rash DMR consists of six hypomethylated CG sites (mean Δβ=−0.12) in the promoter region of precursor microRNA *MIR886* (*VTRNA2-1*).[@R27] Hypomethylation of the *VTRNA2-1* promoter has been shown to downregulate the interferon-inducible phosphorylated RNA-dependent protein kinase which in turn regulates eIF2α and Nuclear Factor kappa B (NF-κB) signalling pathways pivotal to determining cell survival or apoptosis.[@R28] We also found a hypo-DMR in *TRIM69* (two hypomethylated CG sites, mean Δβ=−0.10) whose overexpression has been shown to induce apoptosis in murine models. In patients with a history of discoid rash, we report a DMR in the DNA damage response genes *RHOJ* (2 hypomethylated CG sites, mean Δβ=−0.17) and *HZF* (11 hypermethylated CG sites, mean Δβ=0.16) which are also involved in cell survival/apoptosis pathway commitment. Indeed, the haematopoietic zinc finger encoded by *HZF* is a key cofactor of p53 tumour suppressor and serves as a critical switch promoting cell-cycle arrest over the alternative apoptosis pathway.[@R31] [@R32] Taken together, both cutaneous manifestations are associated with unique DMRs in genes that influence environmental stress response pathways and cell fate decisions. It is unclear what role these DMRs have in cutaneous manifestations in SLE. However, they may provide insight into the impaired apoptotic cell clearance found in the epidermis of patients with cutaneous lupus erythematosus and in germinal centres of patients with SLE.[@R33] [@R34]

Our DMR analyses also revealed a relationship between SLE cutaneous manifestations and antigen processing and presentation. In particular, SLE with discoid rash is associated with hypo-DMR in *PSMB8* (two hypomethylated sites, mean Δβ=−0.13), encoding a subunit of the immunoproteasome involved in processing peptides for MHC-I loading. A hypo-DMR was also found in *TAP1* (four hypomethylated sites, mean Δβ=−0.11) which encodes a key subunit of the transporter associated with antigen processing complex, TAP. In monocytes and dendritic cells, the TAP complex transports phagosome-processed exogenous peptides to the endoplasmic reticulum to bind and present on MHC-I in a process known as cross-presentation.[@R35] Interestingly, our network analyses of unique hypo-DMR in each cutaneous patient subset group showed enrichment in genes functioning in the TAP-dependent antigen processing and presentation of exogenous peptide antigen via MHC-I (malar rash p=3.66×10^−18^, discoid rash p=3.67×10^−13^). MHC-I cross-presentation is commonly used by antigen-presenting cells, and it is unclear what role it may have in CD4+ T cells in SLE. One possibility is that these changes represent epigenetic susceptibility loci that can manifest in other cell types that might be more directly involved in antigen cross presentation. The other possibility is that cross-presentation genes and pathways are aberrantly active in CD4+ T cells in a subset of patients with SLE and might play a different role in the pathogenesis of SLE that is independent of their classical known role in antigen cross-presentation. It is also worth noting that T cells have been previously shown to present antigens on MHC class I and MHC class II,[@R36] and whether this is involved in the pathogenesis of cutaneous SLE remains to be further examined.

In this study, we performed an extensive investigation of naïve CD4+ T cell DNA methylation changes associated with malar rash and discoid rash in SLE. In either of the cutaneous manifestations, we characterised aberrant DNA methylation profiles and identified DMRs in multiple genes that impact environmental stress response and cell fate. In addition, hypo-DMRs of malar rash and discoid rash are enriched in genes involved in the pathway for TAP-dependent exogenous antigen processing and MHC-I cross-presentation. Importantly, we revealed several novel targets of aberrant DNA methylation in naïve CD4+ T cells that might aid in our understanding of SLE and its cutaneous manifestations. Future studies and replication efforts with a larger sample size to detect smaller DNA methylation changes between patients and controls, and to examine other cell subsets relevant to SLE might uncover additional epigenetic susceptibility loci for cutaneous SLE manifestations.
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